P1黏附素C端-鞭毛蛋白融合蛋白鼻内免疫可诱导强效系统与黏膜免疫并保护小鼠抵抗肺炎支原体感染
本研究将肺炎支原体P1黏附素免疫优势C端区域(P1C)与保留TLR5激动活性、内在抗原性降低的截短非致病性大肠杆菌K12鞭毛蛋白(KFD)基因融合,构建重组融合蛋白KFD-P1C。BALB/c小鼠每隔3周鼻内免疫三次,KFD-P1C与P1C+KFD佐剂混合物均较单独P1C显著增强系统和黏膜免疫应答,并显著减轻肺炎支原体攻击后的肺部炎症;融合蛋白虽与混合物无统计学差异,但持续显示更高抗体应答、更强抗原特异性T细胞应答、更快细菌清除和更低组织病理学评分趋势,且免疫后应答至少持续九个月。
要点
- KFD-P1C鼻内免疫可诱导强效、持久的系统与黏膜免疫应答。
- 融合蛋白与抗原-佐剂混合物保护效果相当,且为单组分疫苗设计。
- 融合蛋白持续显示更快细菌清除和更低组织病理学评分的趋势。
核心结论
- KFD-P1C融合蛋白鼻内免疫可诱导强效、持久的系统和黏膜免疫应答,并提供与抗原-佐剂混合物相当的保护。
研究设计与样本
- 研究构建了P1C与KFD基因融合的重组蛋白KFD-P1C,KFD为保留TLR5激动活性且内在抗原性降低的截短非致病性大肠杆菌K12鞭毛蛋白。
- BALB/c小鼠每隔3周鼻内免疫三次,分别给予单独P1C、P1C+KFD混合物或KFD-P1C融合蛋白。
主要发现
- KFD-P1C和P1C+KFD均较单独P1C显著增强系统和黏膜免疫应答,并显著减轻肺炎支原体攻击后的肺部炎症。
- KFD-P1C与P1C+KFD组间无统计学显著差异,但融合蛋白持续显示更高抗体应答、更强抗原特异性T细胞应答、更快细菌清除和更低组织病理学评分的趋势。
- KFD-P1C诱导的体液和抗原特异性T细胞应答在免疫后至少持续九个月。
临床怎么用
- 提示鼻内接种单组分KFD-P1C融合蛋白可作为肺炎支原体疫苗的候选策略,有待进一步临床前与临床验证。
局限性
- 研究仅在小鼠模型中进行,尚未在人体验证。
- KFD-P1C与P1C+KFD混合物之间的差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mycoplasma pneumoniae (M. pneumoniae) is a major cause of community-acquired pneumonia. Rising macrolide resistance and limited preventive strategies highlight the urgent need for effective vaccines. A vaccine eliciting robust mucosal immunity is essential to block bacterial colonization and transmission. Here, we generated a recombinant fusion protein, KFD-P1C, by genetically fusing the immunodominant C-terminal region of the P1 adhesin (P1C) to KFD, a truncated non-pathogenic Escherichia coli K12 flagellin (KF) retaining TLR5 agonistic activity while exhibiting reduced intrinsic antigenicity. BALB/c mice were intranasally immunized three times at 3-week intervals with P1C alone, a P1C + KFD admixture, or the KFD-P1C fusion protein. Both KFD-P1C and P1C + KFD elicited significantly stronger systemic and mucosal immune responses than P1C alone and significantly reduced pulmonary inflammation following M. pneumoniae challenge. Although no statistically significant differences were observed between the KFD-P1C and P1C + KFD groups, the fusion protein consistently showed a trend toward higher antibody responses, stronger antigen-specific T cell responses, faster bacterial clearance, and lower histopathological scores. Notably, KFD-P1C induced humoral and antigen-specific T cell responses that persisted for at least nine months after immunization. Collectively, these findings demonstrate that KFD-P1C elicits robust, long-lasting systemic and mucosal immune responses and provides protection against M. pneumoniae comparable to that achieved by the antigen-adjuvant admixture, while offering the practical advantages of a single-component vaccine design.
引用
- Yang J, Lin T, Lin X, et al. Intranasal immunization with a P1 adhesin C-terminal-flagellin fusion protein elicits robust systemic and mucosal immunity and protects against Mycoplasma pneumoniae infection in a mouse model. Vaccine. 2026. PMID: 42542051. doi:10.1016/j.vaccine.2026.128996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。